Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,943
Total Claims
$2.3M
Drug Cost
1,230
Beneficiaries
$1,875
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+33%
Cost per patient vs peers
$1,875 vs $1,411 avg
+27%
Brand preference vs peers
13.5% vs 10.6% avg
Brand vs Generic
Brand: 2,535 claims · $1.9M
Generic: 16,271 claims · $398K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 133 | $234K |
| Apixaban | 197 | $211K |
| Empagliflozin | 131 | $177K |
| Evolocumab | 159 | $153K |
| Tirzepatide | 47 | $82K |
| Fluticasone/Umeclidin/Vilanter | 72 | $82K |
| Semaglutide | 50 | $81K |
| Rivaroxaban | 46 | $68K |
| Dapagliflozin Propanediol | 54 | $62K |
| Sitagliptin Phosphate | 51 | $49K |
| Umeclidinium Brm/Vilanterol Tr | 55 | $47K |
| Budesonide/Glycopyr/Formoterol | 27 | $40K |
| Mirabegron | 28 | $36K |
| Dulaglutide | 20 | $35K |
| Linagliptin | 25 | $29K |
Prescribing Profile
Patient Profile
74
Avg Age
51%
Female
1.31
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data